Precigen, Inc. Common Stock PGEN

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

• Zacks Investment Research 5 oct

  Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus

  Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.

  

• Zacks Investment Research 2 oct

  4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

  With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

  

• Zacks Investment Research 1 oct

  Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

  Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year.

  

• Zacks Investment Research 30 sept

  uniQure Plunges on Additional Data From Huntington's Disease Study

  uniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls. However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.

  

• Zacks Investment Research 30 sept

  PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

  Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.